-
Five Below Initiated Neutral At BTIG On Valuation
Wednesday, August 24, 2016 - 8:48am | 351Read More...Five Below Inc (NASDAQ: FIVE) shares currently trade at an 82 percent premium to the S&P 500, which BTIG’s Alan Rifkin believes fairly reflects the company’s growth prospects. Rifkin initiated coverage of the company with a Neutral rating. Long Runway For Growth The analyst believes...
-
JDA Software Chooses Blackstone Investment Over Selling Itself To Honeywell
Monday, August 22, 2016 - 12:16pm | 315Read More...JDA Software Group has opted to accept a $570 million equity investment from Blackstone Group LP (NYSE: BX) and New Mountain Capital over selling itself to Honeywell International Inc. (NYSE: HON). A Wall Street Journal report said Honeywell was close to acquiring struggling supply chain...
-
Salesforce Makes Its Tenth Purchase In 12 Months With BeyondCore Deal
Monday, August 22, 2016 - 10:11am | 285Read More...On August 22, salesforce.com, inc. (NYSE: CRM) announced the acquisition of privately held business analytics solution provider, BeyondCore. BTIG’s Joel P. Fishbein, Jr. maintains a Buy rating on salesforce.com, with a price target of $100. Tenth Acquisition In 12 Months “While...
-
Tactile Systems Likely To Expand Sales And Marketing Effort Says BTIG
Monday, August 22, 2016 - 9:30am | 285Read More...While Tactile Systems Technology Inc (NASDAQ: TCMD) has built a profitable platform with a strong sales and marketing channel and solid reimbursement relationships, the company is likely to deploy its recently acquired funds to boost sales and marketing for spurring further sales growth, BTIG...
-
BTIG Previews Workday's Q2 Results, Comments On IBM Deal
Monday, August 22, 2016 - 9:17am | 321Read More...Workday Inc (NYSE: WDAY) is scheduled to report its F2Q17 results on August 24. The company would likely report an in-line quarter and turn profitable by FY18, BTIG’s Joel P. Fishbein said in a report. He maintained a Buy rating on Workday, with a price target of $92. Analyst Fishbein...
-
Geron Shares Seen Range-Bound On Lack Of Major Data Until Late 2017
Friday, August 19, 2016 - 12:28pm | 360Read More...BTIG expects Geron Corporation (NASDAQ: GERN) shares to be range-bound until major data release, potentially in late 2017 or 2018. Geron's lead compound imetelstat, an inhibitor of telomerase partnered with Johnson & Johnson (NYSE: JNJ)'s Janssen showed impressive activity in multiple...
-
BTIG Sets $12 Price Target On Rockwell Medical, Sees 63% Upside
Friday, August 19, 2016 - 12:13pm | 324Read More...BTIG has started coverage on Rockwell Medical Inc (NASDAQ: RMTI) with a Buy and a price target of $12, saying that its lead asset, Triferic, has the potential to replace IV iron in hemodialysis patients. Triferic is indicated to replace iron and maintain hemoglobin in hemodialysis patients versus...
-
Why This Analyst Is Awaiting More Efficacy Signals For Agios Pharma Candidates
Friday, August 19, 2016 - 11:59am | 319Read More...BTIG analyst Ling Wang initiated coverage on Agios Pharmaceuticals Inc (NASDAQ: AGIO) shares with a Neutral rating, citing balanced risk/reward at current levels. The brokerage is waiting for the company to provide definitive efficacy signals on the rare genetic disease (RGD) program before...
-
Tracon's Promising Tumor Treatments Make The Stock A Buy
Friday, August 19, 2016 - 10:58am | 375Read More...The promising efficacy of its tumor treatment earns TRACON Pharmaceuticals Inc (NASDAQ: TCON) a Buy rating and $15 price target from BTIG. Tracon's lead compound, TRC105 (an anti-endoglin antibody) has generated promising efficacy in a variety of solid tumors, including HCC, RCC and angiosarcoma...
-
Ophthotech's Fovista Has Potential To Break Through The 'Therapeutic Ceiling' Of Anti-VEGF Therapies
Friday, August 19, 2016 - 10:48am | 401Read More...BTIG’s Ling Wang believes Ophthotech Corp (NASDAQ: OPHT)'s Fovista has the potential to “break through the therapeutic ceiling of current anti-VEGF therapies.” Wang initiated coverage of the company with a Buy rating and price target of $92. Key Catalysts “We view the...
-
Expect Merrimack Pharma Shares To Be Range-Bound For The Near Term
Friday, August 19, 2016 - 9:22am | 296Read More...The sales ramp-up of Merrimack Pharmaceuticals Inc’s (NASDAQ: MACK) lead compound, ONIVYDE, is expected to be gradual in the current indication, BTIG’s Ling Wang said in a report. He reinitiated coverage of the company with a Neutral rating. Slow Sales Ramp ONIVYDE was approved in...
-
Acceleron Has 2 Phase III Trials With Good Chance Of Success; BTIG Initiates Stock At Buy
Friday, August 19, 2016 - 9:11am | 278Read More...Acceleron Pharma Inc (NASDAQ: XLRN) has two ongoing Phase III trials of luspatercept in lower-risk MDS and beta thalassemia, both of which have a 60 percent probability of success, BTIG’s Ling Wang said in a report. He reinitiated coverage of the company with a Buy rating and a price target...
-
BTIG Thinks Agilent's Transformation Is In The Early Innings
Thursday, August 18, 2016 - 10:25am | 399Read More...BTIG maintains its Buy rating on Agilent Technologies Inc (NYSE: A,) saying that the company's transformation is in its early stages and any weakness in shares on "conservative" fourth-quarter guidance offers a buying opportunity. Agilent reported third-quarter adjusted EPS of $0.49, which was $0....
-
NetApp's Descent Appears To Be Leveling Off, BTIG Says
Thursday, August 18, 2016 - 9:41am | 354Read More...BTIG said the first-quarter results of NetApp Inc. (NASDAQ: NTAP) suggest that "double-digit product revenue declines seen for more than a year are starting to reverse," and modest growth could appear later this fiscal year. The results, which handily beat the Street's consensus, showed that the...
-
Argus Positive On Stocks For The Remainder Of 2016, But BTIG Warns Of A Pullback
Monday, August 15, 2016 - 12:20pm | 350Read More...The stock market is always hard to predict, but it seems like 2016 has been even more of a head-scratcher than usual. After one of the worst starts to any year in history in January and February, the SPDR S&P 500 ETF Trust (NYSE: SPY) now sits up an impressive 7.6 percent on the year. In fact,...
